Ramanand A Subramanian
Overview
Explore the profile of Ramanand A Subramanian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ahn D, Ridinger M, Cannon T, Mendelsohn L, Starr J, Hubbard J, et al.
J Clin Oncol
. 2024 Oct;
43(7):840-851.
PMID: 39475591
Purpose: This phase II study evaluated the efficacy and tolerability of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab for the...
2.
Ahn D, Barzi A, Ridinger M, Samuelsz E, Subramanian R, Croucher P, et al.
Clin Cancer Res
. 2024 Jan;
30(10):2039-2047.
PMID: 38231047
Purpose: Onvansertib is a highly specific inhibitor of polo-like kinase 1 (PLK1), with demonstrated safety in solid tumors. We evaluated, preclinically and clinically, the potential of onvansertib in combination with...
3.
Ritchlin C, Helliwell P, Boehncke W, Soriano E, Hsia E, Kollmeier A, et al.
RMD Open
. 2021 Feb;
7(1).
PMID: 33568556
Objective: Evaluation of the efficacy and safety of guselkumab, a human monoclonal antibody targeting the interleukin-23p19 subunit, in patients with psoriatic arthritis (PsA) through 1 year. Methods: Adults who met...
4.
McInnes I, Rahman P, Gottlieb A, Hsia E, Kollmeier A, Chakravarty S, et al.
Arthritis Rheumatol
. 2020 Oct;
73(4):604-616.
PMID: 33043600
Objective: Guselkumab, a human monoclonal antibody specific to interleukin-23p19, demonstrated efficacy and safety versus placebo through week 24 of the phase III DISCOVER-2 trial in biologic-naive patients with psoriatic arthritis...
5.
Deodhar A, Helliwell P, Boehncke W, Kollmeier A, Hsia E, Subramanian R, et al.
Lancet
. 2020 Mar;
395(10230):1115-1125.
PMID: 32178765
Background: Many patients with psoriatic arthritis have an inadequate response to tumor necrosis factor (TNF) inhibitors. Guselkumab, a specific inhibitor of interleukin-23 (IL-23) via IL-23 p19 subunit binding, significantly improved...
6.
Miller A, Subramanian R, Safi F, Sinert R, Zehtabchi S, Elamin E
J Intensive Care Med
. 2011 Feb;
27(1):25-31.
PMID: 21300671
Introduction: The influenza A 2009 (H1N1) virus is a pandemic respiratory infection commanding international attention. More information is needed on patient demographics, illness severity, and risk indicators. Methods: A total...
7.
Paladino L, Subramanian R, Bonilla E, Sinert R
West J Emerg Med
. 2011 Feb;
11(5):450-5.
PMID: 21293764
Objective: To test the diagnostic use of the triage white blood cell (WBC) count in differentiating major from minor injuries. Methods: We conducted a retrospective study of a prospectively collected...
8.
Paladino L, Subramanian R, Nabors S, Sinert R
Eur J Emerg Med
. 2010 Sep;
18(2):94-8.
PMID: 20842040
Objective: The importance of early recognition of hemorrhagic shock and its effects on outcome have long been recognized. Traditional vital signs are relatively insensitive as early diagnostic markers of hemorrhage....
9.
Wiener S, Sutijono D, Moon C, Subramanian R, Calaycay J, Rushbrook J, et al.
Am J Emerg Med
. 2010 Sep;
28(9):1051-5.
PMID: 20825763
Cocaethylene (CE) is a toxic metabolite that is formed after simultaneous consumption of cocaine and ethanol. This potent stimulant is more toxic than cocaine and has a longer half-life. The...
10.
Paladino L, Subramanian R, Nabors S, Bhardwaj S, Sinert R
J Trauma
. 2010 Jul;
69(1):41-5.
PMID: 20665990
Background: To test the diagnostic utility of the triage serum glucose in differentiating major from minor injuries. Methods: Prospective database at Kings County Hospital, a Level I trauma center, from...